GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Gross-Profit-to-Asset %

Kyverna Therapeutics (Kyverna Therapeutics) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kyverna Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Kyverna Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was $232.59 Mil. Therefore, Kyverna Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

Kyverna Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Kyverna Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Gross-Profit-to-Asset % Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
6.62 9.22 -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial 1.69 - - - -

Competitive Comparison of Kyverna Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Kyverna Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's Gross-Profit-to-Asset % falls into.


Kyverna Therapeutics Gross-Profit-to-Asset % Calculation

Kyverna Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (66.924+75.195)/ 2 )
=0/71.0595
=0.00 %

Kyverna Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (75.195+389.984)/ 2 )
=0/232.5895
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Kyverna Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Website
https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024